Topiramate for Weight Loss: How Much It Works, the Dosing, and Where It Fits Next to GLP-1 Medications

Key Takeaways

• Topiramate produces about 4 to 8% body weight loss over 6 to 12 months at doses of 100 to 200 mg per day.
• It is FDA-approved for weight management only in combination with phentermine (sold as Qsymia).
• Topiramate alone is used off-label, often when GLP-1 medications are not tolerated or accessible.
• Topiramate is a sulfamate-substituted monosaccharide originally approved as an antiepileptic drug in 1996 and later approved for migraine prevention in 2004.
• The weight-loss effect was noticed during epilepsy trials, where patients consistently lost weight as a side effect.

Direct answer (40-60 words)

Topiramate produces about 4 to 8% body weight loss over 6 to 12 months at doses of 100 to 200 mg per day. It is FDA-approved for weight management only in combination with phentermine (sold as Qsymia). Topiramate alone is used off-label, often when GLP-1 medications are not tolerated or accessible.

Table of contents

1. The 30-second answer
2. What topiramate is and why it lowers weight
3. The clinical evidence on topiramate weight loss
4. Standard dose ranges for weight management
5. Topiramate alone vs Qsymia (phentermine plus topiramate)
6. Side-effect profile and the cognitive complaints
7. Who should not take topiramate
8. How topiramate compares to GLP-1 medications
9. Combining topiramate with semaglutide or tirzepatide
10. Cost and access
11. FAQ
12. Footer disclaimers

What topiramate is and why it lowers weight

Topiramate is a sulfamate-substituted monosaccharide originally approved as an antiepileptic drug in 1996 and later approved for migraine prevention in 2004. The weight-loss effect was noticed during epilepsy trials, where patients consistently lost weight as a side effect.

The mechanism is not single-pathway. Topiramate appears to lower weight through several actions:

• Reduced appetite, likely through gamma-aminobutyric acid (GABA) modulation in the hypothalamus
• Reduced food cravings, especially for carbohydrates and sweets
• Increased thermogenesis (slight metabolic rate elevation)
• Possible reduced reward signaling around food, which lowers binge-eating behaviors

Unlike GLP-1 receptor agonists, topiramate does not slow gastric emptying. Patients on topiramate do not feel persistently full. They feel less interested in eating and less driven to seek food, which is a different subjective experience.

The carbonic anhydrase inhibition that topiramate causes is responsible for several of its non-weight side effects (taste changes, kidney stones, paresthesias) and is unrelated to weight loss.

The clinical evidence on topiramate weight loss

Topiramate's weight-loss effect has been documented in multiple randomized trials. The headline numbers:

Study	Dose	Duration	Mean weight loss
Bray et al., Obesity Research, 2003	64 mg/day	24 weeks	5.0%
Bray et al., Obesity Research, 2003	96 mg/day	24 weeks	6.5%
Bray et al., Obesity Research, 2003	192 mg/day	24 weeks	8.0%
Wilding et al., International Journal of Obesity, 2004	192 mg/day	60 weeks	9.1%
Astrup et al., Obesity Research, 2004	96 to 192 mg/day	60 weeks	6.5 to 9.1%

A 2011 meta-analysis (Kramer et al., Obesity) pooled 10 trials and found mean placebo-adjusted weight loss of 5.34 kg (about 11.7 lb) on topiramate monotherapy.

The Qsymia development program (CONQUER trial, Gadde et al., The Lancet, 2011) tested phentermine plus topiramate extended-release. At the highest dose (15 mg phentermine plus 92 mg topiramate), mean weight loss at 56 weeks was 9.8% body weight, compared to 1.2% on placebo.

The dose-response curve is real: more topiramate produces more weight loss, but side effects also increase with dose. The clinical sweet spot is usually 100 to 200 mg per day in divided doses.

Standard dose ranges for weight management

Topiramate is started low and titrated up over 4 to 8 weeks to minimize side effects. A typical schedule:

• Week 1: 25 mg once daily at bedtime
• Week 2: 25 mg twice daily
• Week 3: 50 mg morning, 25 mg evening
• Week 4: 50 mg twice daily
• Week 5 onward: continue at 50 mg twice daily, or escalate to 75 mg twice daily, then 100 mg twice daily as tolerated

The 100 mg twice daily dose (200 mg total) is the most common maintenance dose for weight management. Some providers stop at 100 mg total daily if response is adequate. Doses above 200 mg per day produce diminishing additional weight loss and increasing side effects.

For Qsymia (the FDA-approved phentermine-topiramate combination), the doses are different:

• Starting: 3.75 mg phentermine / 23 mg topiramate ER, once daily for 14 days
• Standard: 7.5 mg phentermine / 46 mg topiramate ER, once daily
• Mid: 11.25 mg phentermine / 69 mg topiramate ER, once daily for 14 days
• High: 15 mg phentermine / 92 mg topiramate ER, once daily

Qsymia uses extended-release topiramate at lower total doses than standalone topiramate weight-management protocols. The phentermine adds an appetite-suppressing stimulant component, which is why the topiramate dose can be lower.

Topiramate alone vs Qsymia (phentermine plus topiramate)

The FDA-approved combination, Qsymia, produces more weight loss than topiramate alone:

Treatment	Mean weight loss at 1 year	FDA approved for weight loss?
Topiramate alone, 192 mg/day	6.5 to 9.1%	No (off-label)
Phentermine alone, 15 mg/day	5 to 7%	Yes, short-term only
Qsymia 15/92 (high dose)	9.8%	Yes
Qsymia 7.5/46 (mid dose)	7.8%	Yes

The combination is more effective because the two drugs target different appetite pathways. Phentermine increases catecholamine release (norepinephrine) which suppresses hunger acutely. Topiramate's GABA modulation reduces food reward and craving. They stack rather than overlap.

Qsymia is also FDA-approved, which means insurance is more likely to cover it. Topiramate alone for weight loss is always off-label, which makes coverage rare.

The trade-off: Qsymia adds the side-effect profile of phentermine (insomnia, anxiety, elevated heart rate, dry mouth) on top of topiramate's. Patients who tolerate stimulants do well on Qsymia. Patients who don't tolerate stimulants often do better on topiramate alone.

Side-effect profile and the cognitive complaints

Topiramate's side-effect profile is well-documented from decades of use in epilepsy and migraine. The frequency and severity vary by dose.

Common side effects (>10% of patients):

• Paresthesias (tingling in fingers, toes, face), 10 to 51%
• Fatigue, 9 to 15%
• Dizziness, 8 to 25%
• Cognitive slowing or word-finding difficulty, 6 to 15%
• Taste changes (carbonated drinks taste flat or metallic), 9 to 15%
• Nausea, 8 to 14%
• Weight loss (the desired effect, but counted as a side effect on label)

Less common but notable (1 to 10%):

• Kidney stones, especially in patients with prior history
• Acute angle-closure glaucoma (rare but a medical emergency)
• Metabolic acidosis (slightly low blood bicarbonate)
• Decreased sweating, with risk of overheating in hot weather
• Mood changes (depression in some, calming in others)

The cognitive side effects are the most patient-reported reason for discontinuation. Patients describe word-finding problems, slowed thinking, and difficulty multitasking. The term "dopamax" is used informally because patients feel mentally slowed.

The cognitive effects are dose-dependent and typically reversible within days to weeks of discontinuation. They tend to be worse at doses above 200 mg per day. Slow titration reduces but does not eliminate the risk.

A 2009 review (Sommer and Fenn, Drugs of Today) found that 21 to 42% of patients on topiramate for any indication report cognitive complaints. Among weight-loss patients, the discontinuation rate due to cognitive effects runs 15 to 25% in clinical trials.

Who should not take topiramate

Absolute contraindications:

• Pregnancy planning or pregnancy. Topiramate is associated with cleft lip and cleft palate when taken in the first trimester. Patients of childbearing potential need reliable contraception during use.
• Known hypersensitivity to topiramate
• History of acute angle-closure glaucoma

Strong relative contraindications:

• History of kidney stones (topiramate increases stone formation about 1.5%)
• Severe liver disease (reduces clearance unpredictably)
• Severe kidney impairment (creatinine clearance under 70 mL/min) without dose adjustment

Caution required:

• History of depression or suicidal ideation. Topiramate has a labeled warning about increased suicidal thoughts.
• Patients taking metformin, SGLT2 inhibitors, or other agents that affect acid-base balance (combination raises metabolic acidosis risk)
• Patients in hot climates or with occupations involving heat exposure (impaired sweating raises heatstroke risk)

The pregnancy risk is the single most important issue for women under 50 considering topiramate for weight loss. The North American Antiepileptic Drug Pregnancy Registry data showed an 11-fold increase in oral cleft risk vs untreated controls. Effective contraception is non-negotiable during topiramate therapy in patients of childbearing potential.

How topiramate compares to GLP-1 medications

The honest comparison: GLP-1 medications produce more weight loss than topiramate, with a different side-effect profile.

Treatment	Mean weight loss at 68 weeks	Common side effects
Tirzepatide 15 mg (SURMOUNT-1)	20.9%	Nausea, vomiting, diarrhea
Semaglutide 2.4 mg (STEP-1)	14.9%	Nausea, vomiting, constipation
Qsymia 15/92	10.5% (56-week data)	Insomnia, paresthesias, dry mouth
Topiramate 192 mg	9.1% (60-week data)	Cognitive effects, paresthesias

GLP-1 medications produce roughly twice the weight loss of topiramate. The side-effect profiles are non-overlapping: GLP-1s cause GI symptoms; topiramate causes cognitive and neurological symptoms.

Topiramate makes sense when:

• GLP-1 medications are not accessible (cost, insurance, supply)
• GLP-1 medications cause intolerable nausea
• The patient has a comorbid condition topiramate also treats (migraine prophylaxis, epilepsy)
• The patient has binge-eating disorder, where topiramate has specific evidence (Claudino et al., Journal of Clinical Psychiatry, 2007)

GLP-1 medications make sense when:

• Maximum weight loss is the goal
• The patient has type 2 diabetes (GLP-1s also improve glycemic control)
• The patient has cardiovascular disease (semaglutide and tirzepatide have cardiovascular outcome data)
• Cognitive side effects are unacceptable

The two are not strictly substitutable. They work differently. Patient preference matters.

Combining topiramate with semaglutide or tirzepatide

Some clinicians add topiramate to a GLP-1 medication in patients who plateau or do not reach goal weight on GLP-1 alone. The combination is off-label and has limited published trial data.

The theoretical rationale is sound. Topiramate reduces food reward and craving through GABA mechanisms. GLP-1 medications reduce appetite through gut-brain signaling. The two pathways do not overlap, so additive effects are plausible.

A small 2023 retrospective case series (Singh et al., Obesity Pillars) reported additional 3 to 5% body weight loss when topiramate 100 mg twice daily was added to patients who had plateaued on semaglutide. The case series was uncontrolled and small (n=42), so the result is suggestive rather than definitive.

Combination concerns:

• Both medications cause nausea in the first weeks of use, so starting them simultaneously is hard to tolerate. Add topiramate only after the patient is stable on GLP-1.
• Both can cause taste changes, which compound and reduce appetite further (which can be desired or excessive).
• Both can cause cognitive symptoms (semaglutide rarely, topiramate frequently). Combined cognitive load can be problematic.
• Pregnancy precautions multiply. Both medications are problematic in pregnancy. Reliable contraception is non-negotiable.

Combination therapy should be a clinical decision, not patient-driven. Self-adding topiramate to GLP-1 therapy without provider supervision is not recommended.

Cost and access

Topiramate is a generic medication. Cash prices at major U.S. retail pharmacies in 2026:

Form	Strength	30-day supply cash price
Topiramate generic tablet	25 mg, 60 tablets	$4 to $15
Topiramate generic tablet	50 mg, 60 tablets	$4 to $20
Topiramate generic tablet	100 mg, 60 tablets	$8 to $30
Topiramate generic tablet	200 mg, 30 tablets	$10 to $35
Topamax brand	100 mg, 60 tablets	$400 to $600
Qsymia brand	7.5/46 mg, 30 capsules	$200 to $300 (often eligible for manufacturer savings program)

Generic topiramate is one of the cheapest weight-management medications available. A full 200 mg per day course costs roughly $20 per month at most pharmacies.

Insurance coverage for topiramate is good when prescribed for migraine or epilepsy (its FDA-approved indications). When prescribed off-label for weight loss, insurance often denies. Most patients pay cash regardless.

Qsymia is more expensive but FDA-approved for weight management. Insurance coverage is mixed but improving. The Qsymia savings program can bring cash price to $98 per month for eligible patients.

For patients who cannot tolerate or afford GLP-1 medications, topiramate (especially generic) is among the cheapest pharmacological weight-loss options. The trade-off is the lower magnitude of effect and the cognitive side-effect risk.

FAQ

How much weight will I lose on topiramate? Most patients lose 4 to 8% of body weight over 6 to 12 months at doses of 100 to 200 mg per day. Higher doses (200 mg or more) push the average closer to 9%. Individual response varies widely, with about 25% of patients losing minimal weight and another 25% losing more than 10%.

What is the typical topiramate dose for weight loss? 100 to 200 mg per day in divided doses, started at 25 mg per day and titrated up over 4 to 8 weeks. The most common maintenance dose is 100 mg twice daily. Doses above 200 mg per day produce diminishing additional weight loss and more side effects.

How long does it take for topiramate to work for weight loss? Appetite reduction often begins within the first 2 to 4 weeks at therapeutic doses (75 mg or higher). Measurable weight loss typically appears at 8 to 12 weeks. Full effect is reached at 6 to 12 months at a stable dose.

Is topiramate FDA-approved for weight loss? Topiramate alone is not FDA-approved for weight loss. The phentermine-topiramate combination (Qsymia) is FDA-approved for chronic weight management. Topiramate alone for weight loss is prescribed off-label.

Why does topiramate cause weight loss? The exact mechanism is not fully mapped, but it appears to involve GABA-mediated appetite suppression, reduced carbohydrate craving, increased thermogenesis, and reduced food reward signaling. Unlike GLP-1 medications, topiramate does not slow gastric emptying.

What are the worst side effects of topiramate? The most common are paresthesias (tingling), cognitive slowing, fatigue, taste changes (carbonated drinks taste flat), and dizziness. The rare but serious side effects include kidney stones, acute angle-closure glaucoma, metabolic acidosis, and decreased sweating.

Can I take topiramate with semaglutide or tirzepatide? The combination is off-label. Some clinicians add topiramate to patients who plateau on GLP-1 medications. There is limited published data on this combination. Discuss with your provider before combining; do not add topiramate on your own.

Is topiramate as effective as Wegovy or Zepbound? No. GLP-1 medications produce roughly twice the weight loss of topiramate at maximum doses. Tirzepatide (Zepbound) averages 20.9% body weight loss; semaglutide (Wegovy) averages 14.9%; topiramate averages 6.5 to 9.1%.

Will I gain the weight back if I stop topiramate? Most patients regain a substantial portion of the lost weight within 12 months of stopping topiramate. Weight maintenance after discontinuation requires diet and behavioral structure that does not depend on the medication. Sustained weight loss generally requires sustained pharmacological treatment.

Can topiramate cause permanent cognitive problems? The cognitive effects of topiramate are typically reversible within days to weeks of discontinuation. There is no published evidence of permanent cognitive impairment from topiramate use at standard doses, even after years of treatment.

Is topiramate safer than phentermine for weight loss? The two have different risk profiles. Phentermine is a stimulant with cardiovascular and addictive concerns. Topiramate is a non-stimulant with cognitive and pregnancy concerns. Neither is universally safer; the right choice depends on the patient.

Can I drink alcohol while taking topiramate? Light to moderate alcohol use is generally allowed but is associated with increased side effects (dizziness, cognitive slowing, fatigue). Heavy drinking should be avoided. Alcohol can also worsen the metabolic acidosis that topiramate sometimes causes.

Why is topiramate called "dopamax"? A patient-coined nickname referring to the cognitive slowing some patients experience: a sense of feeling mentally dulled or "dopey." The term is informal and reflects a real but reversible side effect that affects roughly 15 to 25% of users at therapeutic doses.

Does topiramate work for binge-eating disorder? Yes, with FDA-approved evidence. Topiramate at 100 to 400 mg per day reduces binge-eating frequency in patients with binge-eating disorder. The effect is partly weight-loss-mediated and partly direct on the reward system.

Author / review note

Reviewed by the FormBlends Medical Team. References include Bray et al., Obesity Research, 2003; Wilding et al., International Journal of Obesity, 2004; Gadde et al., The Lancet, 2011 (CONQUER trial); Kramer et al., Obesity, 2011 (meta-analysis); Claudino et al., Journal of Clinical Psychiatry, 2007 (binge-eating disorder); the Qsymia prescribing information (rev. 2023); and the North American Antiepileptic Drug Pregnancy Registry data on topiramate teratogenicity.

Sources

1. Bray et al., Obesity Research, 2003.
2. Wilding et al., International Journal of Obesity, 2004.
3. Gadde et al., The Lancet, 2011 (CONQUER trial).
4. Kramer et al., Obesity, 2011 (meta-analysis).
5. Claudino et al., Journal of Clinical Psychiatry, 2007 (binge-eating disorder).
6. The Qsymia prescribing information (rev. 2023).
7. The North American Antiepileptic Drug Pregnancy Registry data on topiramate teratogenicity.

Footer disclaimers (all 4 verbatim)

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Topamax is a registered trademark of Janssen Pharmaceuticals. Qsymia is a registered trademark of Vivus LLC. Wegovy and Ozempic are registered trademarks of Novo Nordisk A/S. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.